A 5-year overall survival rate for metastatic melanoma has increased substantially from less than 10% to up to 40–50% based on PD-1-based treatment and targeted agents in BRAF V600-mutant melanoma [4, 12–15]. This evidence concerns the gene BRAF and metastatic melanoma.